News

In the News part you can find Company Announcements, press releases and Online news as downloadable PDF files in English and Danish.

Company Announcements

RSS feed - Stock Exchange Announcements

Increased operating profit by 18% in the first quarter of 2013 (1 May 2013)

Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 February 2013)

Novo Nordisk increased operating profit by 32% in 2012 (31 January 2013)

Tresiba® and Ryzodeg® receive marketing authorisations in Europe (21 January 2013)

Ryzodeg® (insulin degludec/insulin aspart) approved in Japan (25 December 2012)

Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan (3 December 2012)

Novo Nordisk increased operating profit by 34% in the first nine months of 2012 (31 October 2012)

Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities (19 October 2012)

Novo Nordisk increased operating profit by 31% in the first half of 2012 (9 August 2012)

Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 (27 April 2012)

Novo Nordisk increased operating profit by 18% in 2011 (2 February 2012)

Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes (7 November 2011)

Novo Nordisk A/S: Interim financial report for the period 1 January 2011 to 30 September 2011 (27 October 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US (29 September 2011)

Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe (26 September 2011)

Novo Nordisk increased operating profit by 27% in 2010 (2 February 2011)

Interim financial report for the period 1 January 2010 to 30 September 2010 (28 October 2010)

Interim financial report for the period 1 January 2010 to 30 June 2010 (5 August 2010)

Interim financial report for the period 1 January 2010 to 31 March 2010 (27 April 2010)

Press Releases

RSS feed - Press Releases

Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation (10 December 2013)

Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 (3 December 2013)

New study demonstrates efficacy throughout 2.5 years for Tresiba® (24 September 2013)

Study confirms improved health-related quality of life for patients with type 2 diabetes receiving Tresiba® (22 June 2013)

Featured stories

RSS feed - Featured stories

No results matching your criteria

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •